SpringWorks Therapeutics Inc. (SWTX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease
SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025.
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $1.18 per share a year ago.
Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in SpringWorks Therapeutics (SWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B
German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics (SWTX) for around $3.9 billion, expanding its portfolio of rare disease and cancer treatments.
SpringWorks Therapeutics (SWTX) Soars 9.0%: Is Further Upside Left in the Stock?
SpringWorks Therapeutics (SWTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz
SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexiform neurofibromas. In fact, Ogsiveo's revenues alone reached $172 million in 2024, supported by orphan drug designations in the US and EU. Similarly, Gomekli is the first FDA-approved MEK inhibitor for NF1‑plexiform neurofibromas, which targets both adults and children.
SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates
SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
SpringWorks Therapeutics (SWTX) Reports Q4 Loss, Tops Revenue Estimates
SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.44 per share a year ago.
SpringWorks Therapeutics (SWTX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
SpringWorks Therapeutics (SWTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down
SpringWorks reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides updates across the commercial portfolio and other pipelines.
SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate
SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024, and potential EMA approval if it could boost sales further. Mirdametinib, a MEK inhibitor for NF1-PN, has a PDUFA date of February 28th of 2025, and could unlock significant shareholder value if approved. Results from phase 1b study using brimarafenib to treat patients with MAPK mutant solid tumors are expected to be released in the 2nd half of 2025.
Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?
SpringWorks Therapeutics (SWTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
